Entacapone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Entacapone: From Parkinson’s Disease to PLA2G6-Associated Neurodegeneration
One-Sentence Summary
Entacapone is a peripherally-acting COMT inhibitor used as adjunct therapy to levodopa/carbidopa in Parkinson’s disease. The TxGNN model predicts it may be effective for PLA2G6-associated neurodegeneration, but this prediction is currently model-only — no clinical trials or literature support it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Parkinson’s disease (adjunct to levodopa/carbidopa) — inferred from narrative text within this evidence pack; not confirmed by an official label field |
| Predicted New Indication | PLA2G6-associated neurodegeneration |
| TxGNN Prediction Score | 99.76% |
| Evidence Level | L5 |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for entacapone is not confirmed within this evidence pack — it is flagged as a High-severity data gap (DG002). Based on information referenced elsewhere in the pack, entacapone is understood to be a peripheral, reversible COMT (catechol-O-methyltransferase) inhibitor, approved as adjunct therapy to levodopa/carbidopa in Parkinson’s disease, where it prolongs the central availability of levodopa.
PLA2G6-associated neurodegeneration (PLAN) belongs to the NBIA (Neurodegeneration with Brain Iron Accumulation) disease spectrum, characterized by iron deposition and progressive neurodegeneration. Some patients present with parkinsonian features, giving a theoretical overlap with the dopamine pathway that entacapone acts on.
However, the model’s own rationale explicitly notes there is no clinical or literature evidence tying entacapone to PLAN — the theoretical overlap in symptomatology is not the same as mechanistic validation. This should be treated as a low-confidence signal, possibly model noise, rather than a supported hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
Entacapone currently has 0 SAHPRA registrations on file and is not marketed in South Africa per this evidence pack. No product/dosage-form data is available.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The top-ranked prediction (PLA2G6-associated neurodegeneration) has a high TxGNN score but zero supporting clinical trials or literature (Evidence Level L5) — it is a pure model output, not a validated repurposing signal.
To proceed, the following is needed:
- SAHPRA-approved Professional Information (warnings/contraindications) — currently a Blocking data gap (DG001), required before any S1 safety screening can occur.
- Confirmed mechanism-of-action data (DG002) to properly assess mechanistic plausibility.
- Preclinical or mechanistic studies specifically linking COMT inhibition to PLAN pathology.
- Given the complete absence of route/dosage data, route compatibility for this rare pediatric-onset condition would also need to be established.
Note: Among the 10 TxGNN candidates in this evidence pack, two other predictions — Lewy body dementia (rank 7) and paralysis agitans, juvenile, of Hunt (rank 4) — reached Evidence Level L4 / decision stage S1 (“Research Question”), each supported by at least indirect clinical-trial or literature context tied to dopaminergic pathways. These may warrant separate evaluation as more promising candidates than the top-ranked-by-score prediction covered here.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.